PharmTech spoke with Andrew Mitchell, associate vice president of Business Development at BioVectra, about which 2025 trends will continue to impact the pharma industry and how CDMOs can offer solutions.
Andrew Mitchell
Advertisement
Andrew Mitchell is associate vice president of Business Development at BioVectra.
Articles by Andrew Mitchell
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Renewing Prosaic Generics for Cancer Treatment
2
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
3
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
4
PharmTech Weekly Roundup—June 5, 2026
5